Company intelligence / Profile preview

Elysian Bio

Ownership: Private
Development stage: Preclinical

Overview

Elysian Bio is a pioneering biopharmaceutical company focused on improving access to high-quality biologic and biosimilar medicines across Latin America. The company partners with global developers to register, launch, market, and distribute these therapies regionally. Their mission centers on addressing unmet medical needs—especially for cancer patients—by overcoming barriers to access through international partnerships and robust local infrastructure. Backed by Grupo TRACSA and Saya Bio, they leverage strong financial support and regional expertise.

Therapeutic areas: OncologyOther
Modalities: BiologicsBiosimilars
Industry: Drug Discovery Services

Partnerships

Global biosimilar developers seeking LATAM commercialization partnersEstablished pharma companies aiming to expand their biologic presence in the region

Beyond the preview

Go deeper on Elysian Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elysian Bio.

Explore the full profile